Cargando…
EGFR expression in patients with stage III colorectal cancer after adjuvant chemotherapy and on cancer cell function
The epidermal growth factor receptor (EGFR)/RAS/RAF/MEK/MAPK pathway plays a crucial role in the carcinogenesis, invasion and metastasis of colorectal cancer (CRC). However, its role in the prognosis and prediction of relapse in patients with stage III CRC after adjuvant chemotherapy remains controv...
Autores principales: | Huang, Ching-Wen, Chen, Yi-Ting, Tsai, Hsiang-Lin, Yeh, Yung-Sung, Su, Wei-Chih, Ma, Cheng-Jen, Tsai, Tsen-Ni, Wang, Jaw-Yuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777722/ https://www.ncbi.nlm.nih.gov/pubmed/29383110 http://dx.doi.org/10.18632/oncotarget.23072 |
Ejemplares similares
-
Prognostic Value of EGFR Expression for Patients With Stage III Colorectal Cancer Receiving Fluoropyrimidine Metronomic Maintenance Therapy After Radical Resection and Adjuvant Oxaliplatin-Based Chemotherapy
por: Huang, Ching-Wen, et al.
Publicado: (2021) -
High blood sugar levels but not diabetes mellitus significantly
enhance oxaliplatin chemoresistance in patients with stage III colorectal cancer
receiving adjuvant FOLFOX6 chemotherapy
por: Yang, I-Ping, et al.
Publicado: (2019) -
Clinicopathological Features and Oncological Outcomes of Early and Late Recurrence in Stage III Colorectal Cancer Patients after Adjuvant Oxaliplatin-Based Therapy
por: Chang, Yu-Tang, et al.
Publicado: (2023) -
Maintenance tegafur-uracil versus observation following an adjuvant oxaliplatin-based regimen in patients with stage III colon cancer after radical resection: study protocol for a randomized controlled trial
por: Yeh, Yung-Sung, et al.
Publicado: (2017) -
GALNT14 Genotype Predicts Postoperative Outcome of Stage III Colorectal Cancer With Oxaliplatin as Adjuvant Chemotherapy
por: Lin, Wey-Ran, et al.
Publicado: (2016)